These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 17336964)

  • 1. The effect of raloxifene in association with vitamin D on vaginal maturation index and urogenital symptoms in postmenopausal osteoporotic women.
    Zeyneloglu HB; Oktem M; Haberal NA; Esinler I; Kuscu E
    Fertil Steril; 2007 Aug; 88(2):530-2. PubMed ID: 17336964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Effects of SERMs on bone health. Combination therapy with raloxifene].
    Gorai I; Hori H
    Clin Calcium; 2010 Mar; 20(3):408-12. PubMed ID: 20190371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of raloxifene on the vaginal epithelium of postmenopausal women.
    Delmanto A; Nahas-Neto J; Nahas EA; de Oliveira ML; Fernandes CE; Traiman P
    Eur J Obstet Gynecol Reprod Biol; 2008 Aug; 139(2):187-92. PubMed ID: 18400357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A comparison of raloxifene and calcium plus vitamin D on vaginal atrophy after discontinuation of long-standing postmenopausal hormone therapy in osteoporotic women. A randomized, masked-evaluator, one-year, prospective study.
    Checa MA; Garrido A; Prat M; Conangla M; Rueda C; Carreras R
    Maturitas; 2005 Sep; 52(1):70-7. PubMed ID: 16143228
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the effects of raloxifene and low-dose hormone replacement therapy on bone mineral density and bone turnover in the treatment of postmenopausal osteoporosis.
    Dane C; Dane B; Cetin A; Erginbas M
    Gynecol Endocrinol; 2007 Jul; 23(7):398-403. PubMed ID: 17701771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Influence of the selective oestrogen receptor modulator (raloxifene hydrochloride) on IL-6, TNF-alpha, TGF-beta1 and bone turnover markers in the treatment of postmenopausal osteoporosis.
    Ozmen B; Kirmaz C; Aydin K; Kafesciler SO; Guclu F; Hekimsoy Z
    Eur Cytokine Netw; 2007 Sep; 18(3):148-53. PubMed ID: 17823083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Vitamin D deficiency in postmenopausal women receiving osteoporosis therapy].
    Kraljević I; Kastelan D; Gorsić I; Solak M; Giljević Z; Kasović M; Sertić J; Korsić M
    Lijec Vjesn; 2007; 129(8-9):304. PubMed ID: 18198632
    [No Abstract]   [Full Text] [Related]  

  • 8. [Current osteoporosis treatment: reasons for adding vitamin D to alendronate].
    Anić B; Grazio S
    Reumatizam; 2006; 53(2):63-5. PubMed ID: 17580557
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Evidence for the selective estrogen receptor modulator raloxifene: its evolving role in the treatment of osteoporosis].
    Ohta H
    Clin Calcium; 2008 Oct; 18(10):1442-50. PubMed ID: 18830041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [FOSAVANCE -- alendronate plus vitamin D in a weekly tablet].
    Praxis (Bern 1994); 2006 Jul; 95(27-28):2 p following 1084. PubMed ID: 16888927
    [No Abstract]   [Full Text] [Related]  

  • 11. Effects of raloxifene on adipocytokines in Japanese osteoporotic postmenopausal women with and without type 2 diabetes.
    Murase Y; Kobayashi J; Asano A; Yamaaki N; Yonezawa K; Muramoto H; Mabuchi H
    Horm Metab Res; 2006 Feb; 38(2):130-3. PubMed ID: 16523415
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluation of the sexual function and quality of life in raloxifene treated postmenopausal women.
    Biri A; Korucuoglu U; Ilhan MN; Ciftci B; Bozkurt N; Guner H
    Arch Gynecol Obstet; 2009 Apr; 279(4):505-9. PubMed ID: 18690468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationship between bone mass, invasive breast cancer incidence and raloxifene therapy in postmenopausal women with low bone mass or osteoporosis.
    Burshell AL; Song J; Dowsett SA; Mershon JL; Delmas PD; Secrest RJ; Cauley JA
    Curr Med Res Opin; 2008 Mar; 24(3):807-13. PubMed ID: 18254988
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Assessment of bone quality. Bone quality and osteoporosis treatment].
    Mashiba T
    Clin Calcium; 2008 Mar; 18(3):300-7. PubMed ID: 18310816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of raloxifene and hormone replacement therapy on forearm skin elasticity in postmenopausal women.
    Sumino H; Ichikawa S; Kasama S; Takahashi T; Kumakura H; Takayama Y; Kanda T; Murakami M; Kurabayashi M
    Maturitas; 2009 Jan; 62(1):53-7. PubMed ID: 19042101
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Long term effects of raloxifen on the bones].
    Eiken PA
    Ugeskr Laeger; 2008 Jan; 170(4):224-6. PubMed ID: 18282451
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Raloxifene in clinical practice. Results of the non-interventional study CORAL (COmpliance with RALoxifene)].
    Rosa J; Vanuga P; Payer J; Svobodník A
    Vnitr Lek; 2008 Mar; 54(3):217-9, 221-4. PubMed ID: 18522288
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evidence that treatment with risedronate in women with postmenopausal osteoporosis affects bone mineralization and bone volume.
    Fratzl P; Roschger P; Fratzl-Zelman N; Paschalis EP; Phipps R; Klaushofer K
    Calcif Tissue Int; 2007 Aug; 81(2):73-80. PubMed ID: 17612779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Treatment of osteoporosis with antiresorptive drugs].
    Vestergaard P; Mosekilde L; Brixen K
    Ugeskr Laeger; 2005 Feb; 167(8):883-7. PubMed ID: 15789840
    [No Abstract]   [Full Text] [Related]  

  • 20. The effect of alendronate, risedronate, and raloxifene on renal functions, based on the Cockcroft and Gault method, in postmenopausal women.
    Yanik B; Bavbek N; Yanik T; Inegöl I; Kanbay M; Turgut FH; Uz E; Akçay A
    Ren Fail; 2007; 29(4):471-6. PubMed ID: 17497471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.